The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ps.41.12.1330

As the number of people over age 65 continues to grow, a clear understanding of the usefulness and limitations of psychostimulants in treating elderly persons becomes more important. The authors review the limited literature and discuss the use of psychostimulants for treating "senility," including their effects on cognition, amotivational syndromes, and depression. They conclude that early studies of "senile" patients suffered from a lack of clear diagnostic standards and did not address the issue of whether measurements of the target symptoms being assessed were reliable or valid. The authors suggest that future studies more clearly define age groups, diagnostic criteria, and scales to measure the effects of psychostimulants.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.